The Efficacy of Acupuncture and Laser Acupuncture in Treating Chemotherapy or Target Therapy-induced Hand-foot Syndrome

Sponsor
China Medical University Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05949307
Collaborator
(none)
60
3
7.9

Study Details

Study Description

Brief Summary

Chemotherapy or target therapy-induced hand-foot syndrome in cancer patients affects the quality of life. At present, there is no better treatment for this side effect of chemotherapy or target therapy. In severe cases, it is necessary to reduce the dose of chemotherapy or target therapy, which may affect the progress and effect of chemotherapy. In recent years, acupuncture has been widely used for many side effects of chemotherapy, such as numbness of hands and feet, gastrointestinal discomfort, and dizziness. There have been many studies have proved to be effective, but quite few studies explored the acupuncture treatment improves the hand-foot syndrome caused by chemotherapy or target therapy in cancer patients. Therefore, the investigators expect to evaluate the efficacy of acupuncture, and applying acupuncture or laser acupuncture to improve hand-foot syndrome caused by chemotherapy or target therapy in cancer patients in the future.

Condition or Disease Intervention/Treatment Phase
  • Device: acupuncture
  • Device: laser acupuncture
  • Device: Sham-laser acupuncture
N/A

Detailed Description

The investigators design a single-center, sham-controlled, assessor- and subject- blind, randomized clinical trial. 60 subjects will be equally and randomly divided into an acupuncture group, laser acupuncture, and sham-laser acupuncture groups in the 6-week trial. Each subject receives acupuncture, laser acupuncture, or sham-laser acupuncture three times a week for three consecutive weeks depending on their group, with a total of 9 times interventions. Outcome measures include Common adverse events evaluation standard version 5.0 (CTCAE) and Visual Analogue Scale (VAS), Dermatology Life Quality Index (DLQI) and assessment of cancer patients' quality of life questionnaire (EORTC QLQ-C30). ANSWatch and Thermal Image Camera are also used to assess those subjects. Those outcome measures will be conducted at baseline, the 3rd and the 6th week after the interventions.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Efficacy of Acupuncture and Laser Acupuncture in Treating Chemotherapy or Target Therapy-induced Hand-foot Syndrome
Anticipated Study Start Date :
Aug 1, 2023
Anticipated Primary Completion Date :
Mar 29, 2024
Anticipated Study Completion Date :
Mar 29, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Acupuncture group

receive acupuncture treatment

Device: acupuncture
acupuncture

Experimental: Laser acupuncture group

receive laser acupuncture treatment

Device: laser acupuncture
laser acupuncture

Sham Comparator: Sham laser acupuncture group

receive sham-laser acupuncture treatment

Device: Sham-laser acupuncture
Sham-laser acupuncture

Outcome Measures

Primary Outcome Measures

  1. The change of Common Terminology Criteria for Adverse Events (CTCAE) version 5. 0 [Change from Baseline severity of hand-foot syndrome at 3 weeks]

    Evaluate skin symptoms assessed by Common Terminology Criteria for Adverse Events version 5. 0 (total three grade. Grade 1 is minimal skin changes, and grade 3 is severe skin changes)

  2. The change of scores of Visual analogue scale (VAS) [Change from Baseline severity of pain at 3 weeks]

    pain evaluation assessed by Visual analogue scale, score from 0 (no pain) to 10 (unbearable pain)

  3. The change of Dermatology Life Quality Index (questionnaire) [Change from Baseline quality of life at 3 weeks]

    evaluate quality of life assessed by Dermatology Life Quality Index

  4. The change of EORTC QLQ-C30 (questionnaire) [Change from Baseline quality of life at 3 weeks]

    evaluate quality of life assessed by EORTC QLQ-C30

  5. The change of LF/HF before and after treatment [Change from Baseline LF/HF at 3 weeks]

    testing LF/HF assessed by ANSWatch wrist monitor

  6. The change of temperature of limbs before and after treatment [Change from Baseline temperature at 3 weeks]

    testing temperature assessed by Thermal Imaging Analysis

Secondary Outcome Measures

  1. The change of Common Terminology Criteria for Adverse Events (CTCAE) version 5. 0 [Change from Baseline severity of hand-foot syndrome at 6 weeks]

    Evaluate skin symptoms assessed by Common Terminology Criteria for Adverse Events version 5. 0 (total three grade. Grade 1 is minimal skin changes, and grade 3 is severe skin changes)

  2. The change of scores of Visual analogue scale (VAS) [Change from Baseline severity of pain at 6 weeks]

    pain evaluation assessed by Visual analogue scale, score from 0 (no pain) to 10 (unbearable pain)

  3. The change of Dermatology Life Quality Index (questionnaire) [Change from Baseline quality of life at 6 weeks]

    evaluate quality of life assessed by Dermatology Life Quality Index

  4. The change of EORTC QLQ-C30 (questionnaire) [Change from Baseline quality of life at 6 weeks]

    evaluate quality of life assessed by EORTC QLQ-C30

  5. The change of LF/HF before and after treatment [Change from Baseline LF/HF at 6 weeks]

    testing LF/HF assessed by ANSWatch wrist monitorng LF/HF

  6. The change of temperature of limbs before and after treatment [Change from Baseline temperature at 6 weeks]

    testing temperature assessed by Thermal Imaging Analysis

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Cancer patients receiving chemotherapy or targeted therapy

  2. Age over 20 years old

  3. Western medicine diagnoses hand-foot syndrome

  4. Sign the consent form

Exclusion Criteria:
  1. Pregnant or planning to become pregnant

  2. Serious arrhythmia (or cardiac pacemaker installed)

  3. Epilepsy

  4. Severe organ failure, such as heart and lung failure, liver and kidney failure

  5. Psychiatric history, unable to cooperate with acupuncture and assessors

  6. Those who received traditional Chinese medicine treatment for hand-foot skin reaction

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • China Medical University Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yu-Chen Lee, Chief and Attending Physician, China Medical University Hospital
ClinicalTrials.gov Identifier:
NCT05949307
Other Study ID Numbers:
  • CMUH112-REC1-020
First Posted:
Jul 18, 2023
Last Update Posted:
Jul 18, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yu-Chen Lee, Chief and Attending Physician, China Medical University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 18, 2023